共 50 条
- [21] Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or EthnicityJOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (04) : 336 - 344Flamm, Steven L.Muir, Andrew J.Fried, Michael W.Reddy, K. RajenderNelson, David R.Bzowej, Natalie H.Sullivan, James C.Bengtsson, LeifDeMasi, RalphWright, Christopher I.Kieffer, Tara L.George, ShelleyAdda, NathalieDusheiko, Geoffrey M.
- [22] Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naive Genotype 1b Chronic Hepatitis C PatientsGASTROENTEROLOGY RESEARCH AND PRACTICE, 2014, 2014Abe, HiroshiTsubota, AkihitoShimada, NoritomoAtsukawa, MasanoriKato, KeizoTakaguchi, KoichiAsano, ToruChuganji, YoshimichiSakamoto, ChoitsuToyoda, HidenoriKumada, TakashiIde, TatsuyaSata, MichioAizawa, Yoshio
- [23] Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naive patients with HCV genotype 1: phase 3 COMMAND-3 resultsJOURNAL OF VIRAL HEPATITIS, 2014, 21 : 7 - 8Jacobson, I.Zeuzem, S.Flisiak, R.Knysz, B.Lueth, S.Zarebska-Michaluk, D.Janczewska, E.Ferenci, P.Diago, M.Zignego, A.Safadi, R.Baruch, Y.Abdurakhmanov, D.Shafran, S.Thabut, D.Bruck, R.Gadano, A.Thompson, A.Kopit, J.McPhee, F.Michener, T.Hughes, E.Yin, P.Noviello, S.
- [24] Approach to the Treatment-naive Patient with HCV Genotype 1 InfectionINFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2012, 26 (04) : 893 - +Muir, Andrew J.
- [25] EFFICACY AND SAFETY OF TELAPREVIR-BASED REGIMENS IN CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: SUBANALYSIS OF THE REALIZE PHASE III STUDYHEPATOLOGY, 2011, 54 : 374A - 375APol, StanislasRoberts, Stuart K.Andreone, PietroYounossi, Zobair M.Diago, MoisesLawitz, EricFocaccia, RobertoFoster, Graham R.Horban, AndrzejLonjon-Domanec, IsabelleDeMasi, Ralphvan Heeswijk, RolfDe Meyer, SandraPicchio, GastonWitek, JamesZeuzem, Stefan
- [26] Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE studyALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (02) : 124 - 133Vera-Llonch, M.Martin, M.Aggarwal, J.Donepudi, M.Bayliss, M.Goss, T.Younossi, Z.
- [27] Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III studyJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 177 - 177Roberts, StuartPol, StanislasAndreone, PietroYounossi, ZobairDiago, MoisesLawitz, Eric J.Focaccia, RobertoFoster, Graham R.Horban, AndrzejLonjon-Domanec, IsabelleDemasi, RalphHeeswijk, Rolf V.Meyer, Sandra D.Picchio, GastonWitek, JamesZeuzem, Stefan
- [28] Clinical virology findings from treatment-naive and treatment-experienced genotype 1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase 3 clinical trialsANTIVIRAL THERAPY, 2011, 16 : A27 - A27Kieffer, T. L.De Meyer, S.Bartels, D. J.Sullivan, J. C.Dierynck, I.Adda, N.Kwong, A.Jacobson, I. M.Sherman, K. E.Zeuzem, S.Picchio, G.
- [29] Telaprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with genotype 1 HCV and mild to moderate liver diseaseHEPATOLOGY, 2013, 58 : 1129A - 1129AZeuzem, StefanDeMasi, RalphFoster, Graham R.Buti, MariaLaeuffer, Joerg M.Luo, DonghanWitek, JamesRizzetto, Mario
- [30] TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE-1 HCV INFECTION: PHARMACOKINETIC RESULTS OF ADJUSTED DOSING WITH TACROLIMUS OR CYCLOSPORINE IN THE TELAPREVIR REPLACE STUDYJOURNAL OF HEPATOLOGY, 2014, 60 (01) : S481 - S482Forns, X.Samuel, D.Mutimer, D.Fagiouli, S.Navasa, M.Agarwal, K.Berenguer, M.Colombo, M.Herzer, K.Nevens, F.Daems, B.Luo, D.Witek, J.Bertelsen, K.